Moderna, Merck cancer vaccine shows promise in late-stage trial; Moderna stock more than doubles
The combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone.
Moderna's cancer vaccine, developed in partnership with Merck, has shown promising results in a late-stage trial. The vaccine, when used in combination with Merck's Keytruda, significantly extended the time patients lived without their melanoma returning, compared to those treated with Keytruda alone. This is a notable achievement, as it suggests that the vaccine could be a valuable addition to the treatment options for patients with melanoma.
The success of this trial is also a boost for Moderna, whose stock has more than doubled in value. The company's focus on developing messenger RNA (mRNA) technology for various therapeutic applications, including cancer, has been a key driver of investor interest. The positive results from this trial provide further validation of Moderna's approach and could pave the way for future approvals and partnerships.
As investors look ahead, the next key milestone for Moderna will be the potential FDA approval of its cancer vaccine. The company will need to continue to demonstrate the safety and efficacy of the vaccine in larger patient populations and potentially in other cancer types. Additionally, investors will be watching to see how Moderna's technology can be applied to other areas, such as infectious diseases, and whether the company can maintain its momentum in the highly competitive biotech industry.
Originally reported by cnbc.com. ExpoNews adds analysis for finance & markets readers.